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Adult T cell leukemia (ATL) is an aggressive T cell malignancy caused by human T cell leukemia virus type 1 (HTLV-1)
and has a poor prognosis. We analyzed the cytotoxic effects of various nucleoside analog reverse transcriptase
inhibitors (NRTIs) for HIV-1 on ATL cells and found that abacavir potently and selectively kills ATL cells. Although
NRTIs have minimal genotoxicities on host cells, the therapeutic concentration of abacavir induced numerous DNA
double-strand breaks (DSBs) in the chromosomal DNA of ATL cells. DSBs persisted over time in ATL cells but not in
other cell lines, suggesting impaired DNA repair. We found that the reduced expression of tyrosyl-DNA phospho-
diesterase 1 (TDP1), a repair enzyme, is attributable to the cytotoxic effect of abacavir on ATL cells. We also showed
that TDP1 removes abacavir from DNA ends in vitro. These results suggest a model in which ATL cells with reduced
TDP1 expression are unable to excise abacavir incorporated into genomic DNA, leading to irreparable DSBs. On the
basis of the above mechanism, we propose abacavir as a promising chemotherapeutic agent for ATL.
INTRODUCTION
Adult T cell leukemia (ATL) is caused by human T cell leukemia virus
type 1 (HTLV-1) (1–3). Because of resistance to most cytotoxic drugs,
patients suffering from ATL have an extremely poor prognosis with
conventional chemotherapy [3-year overall survival rate of 24% (4, 5)].
Even allogeneic hematopoietic stem cell transplantation only increases
the 3-year overall survival rate to a modest 33% (6). The combination
of azidothymidine (AZT, also called zidovudine) and interferon-a
(IFN-a), first proposed by Gill et al. (7) and Hermine et al. (8), is
currently considered the most effective therapy, with an overall 5-year
survival rate that reaches 46% (9). Some speculate that this combination
therapy represses ATL cells by activating the immune response against
HTLV-1–infected ATL cells as well as by interfering with the produc-
tive replication of HTLV-1 (10). However, the molecular mechanism
underlying the cytotoxic effect of AZT against ATL remains elusive.
AZT is a first-generation nucleoside analog reverse transcriptase
inhibitor (NRTI) (11) and has been widely used for HIV-1 patients.
NRTI is efficiently incorporated into newly synthesizing viral DNA by
HIV-1 reverse transcriptase, but not by replicative DNA polymerases
in host cells. Efficient incorporation by reverse transcriptase is attrib-
utable to a lack of proofreading activity as well as to less stringent dis-
crimination (12). Incorporated NRTIs prevent further extension of DNA
synthesis, thereby inhibiting the productive replication of HIV-1. NRTIs
approved for the treatment of HIV-1 are believed to have a minimal
genotoxic effect on host cells.
Tyrosyl-DNA phosphodiesterase 1 (TDP1) was initially identified
as a key enzyme for eliminating covalently bound topoisomerase I
(TopI) from cleaved DNA ends (13). A mutation in the TDP1 gene
causes spinocerebellar ataxia with axonal neuropathy (SCAN1). A de-
fect in TDP1 causes hypersensitivity to camptothecin (CPT11), a chemo-
therapeutic TopI poison, which stabilizes the covalent binding of TopI
to cleaved DNA ends and kills cancer cells by inducing double-strand
breaks (DSBs) during DNA replication, as shown in both SCAN1 patient–
derived cell lines and knockout mouse models (14, 15).
Here, we found that a therapeutic concentration of abacavir (ABC),
an NRTI, induces chromosomal DSBs and thereby kills ATL cells but
not non–HTLV-1–infected cells. ABC is widely used as a key drug for
the treatment of HIV-1 infection because it is well tolerated by >90%
of patients with few adverse effects and has a desirable bioavailability
(16). Once ABC is incorporated into the cells, it is phosphorylated in a
unique stepwise anabolism to be converted to the triphosphated guanine
analog carbovir (CBV) (17). The therapeutic concentration (16, 18, 19)
of ABC causes a marked increase in the number of DSBs. We here dem-
onstrate that this pronounced accumulation of DSBs caused by ABC
results primarily from the down-regulation of TDP1 in ATL cells. We
thus propose ABC as a novel and potent therapeutic agent for ATL.
RESULTS
ABC selectively kills HTLV-1–infected cells, including ATL cells
We first examined the cytotoxic effects of sixNRTIs (ddI, d4T, 3TC,AZT,
TDF, and ABC), all of which are current therapeutic agents for HIV-1, on
ATL cell lines [ED-40515(−), ED-40515(+), SYK-11L(+), and ATL-43T]
and on HTLV-1–infected cell lines (MT-2 and Hut-102). AZT was toxic
to the ED-40515(−), SYK-11L(+), ATL-43T, and MT-2 cell lines but not
to the others, whereas ddI, d4T, 3TC, and TDF showed poor cytotoxicity
(Fig. 1A). Strikingly, the clinically relevant concentrationofABCwashighly
toxic to all ATL- andHTLV-1–infected cell lines but not to non–HTLV-1–
infected cell lines (Jurkat, H9, and SU-DHL-6) (Fig. 1, A and B, fig. S1, and
table S1). We confirmed the cytotoxicity of ABC to MT-2 cells by cell
counting assays as well as MTS assay (fig. S2) because the mitochondrial
toxicity of the NRTIs (20) could have affected the MTS assay. Because
IFN-a is combined with AZT to treat ATL patients (7–9), we also tested
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the synergistic effect of IFN-awithAZTandABC. IFN-a didnot enhance
the lethality of either AZT or ABC in either MT-2 or ED-40515(−) cells
(Fig. 1C), suggesting that the cytotoxic effect of IFN-a in vivo may not
be by a direct action (10).We therefore conclude that ABCpotently and
selectively kills HTLV-1–infected cells, including ATL cells, in vitro.
We next examined the effect of ABC on cell cycle and apoptosis in
ATL cells. ABC induced S/G2-phase arrest and apoptosis in ED-40515(−)
cells, but not in Jurkat cells (Fig. 2, A to C, and fig. S3). This finding
suggests that ABC may cause DNA damage by prematurely terminat-
ing the replication of host chromosomal DNA, thereby activating the
Fig. 1. ABC selectively kills HTLV-1–infected and ATL cell lines. (A) Viability of
the indicated cells after treatment (2 and 4 days) with 100 mM of the indicated
NRTI. MTS values of treated cells relative to untreated cells are shown. Results are
expressed as means ± SD of three independent experiments. (B) Viability of the indicated cells after treatment (2 days) with the indicated ABC dose. MTS
values of treated cells relative to untreated cells are shown. (C) MT-2 and ED-40515(−) cells were treated with ABC or AZT together with IFN-a (0, 100, or
1000 IU/ml) for 2 days and analyzed with an MTS assay. MTS values of treated cells relative to untreated cells are shown.
Fig. 2. ABC induced S/G2-phase arrest and apoptosis. (A) Flow cy-
tometry was used to analyze cell cycle status after propidium iodide
(PI) staining. ED-40515(−) and Jurkat cells were treated with and without
100 mM ABC for 2 days and analyzed using flow cytometry. Results are
expressed as means ± SD of three independent experiments. (B) Repre-
sentation of flow cytometric analysis of cell cycle after PI staining. (C) Flow
cytometric analysis of apoptosis after annexin V and PI double staining.
ED-40515(−), MT-2, Hut-102, ATL-43T, and Jurkat cells were treated with
the indicated dose of ABC or Adriamycin (ADR; 1 mg/ml) for 48 hours. Dark
and light bars represent early and late apoptosis, respectively. Results are
expressed as means ± SD of three independent experiments.
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Fig. 3. ABC-induced DSB accumula-
tion in ATL cells as a result of the
impairment of DNA repair. (A) Chro-
mosome breaks induced by ABC. ED-
40515(−) cells treatedwith 100mMABC
for 2 days were evaluated for chro-
mosome breaks (yellow arrow). (B) ED-40515(−) and Jurkat cells were treated with the indicated doses of ABC and AZT for 2 days. Percentages of chromosome
break–positive cells are shown.Results areexpressedasmeans±SDof three independentexperiments. n.s., not significant. (C) ExpressionkineticsofgH2AX foci after
acute exposure to ABC. ED-40515(−) and Jurkat cells were treated with 500 mM ABC for 12 hours. After treatment, the cells were stained with 4′,6-diamidino-2-
phenylindole (DAPI) and anti-gH2AX at the indicated times. (D) Percentages of gH2AX focus–positive cells at the indicated times. Focus-positive cells are those con-
taining more than five gH2AX foci. (E) Cell proliferation of ED-40515(−) and Jurkat cells based on an MTS assay. MTS values relative to time zero are shown. (F)
Expression kinetics of gH2AX foci at the indicated times after 2-Gy g-irradiation. Irradiated ED-40515(−) and Jurkat cells were stained with DAPI and gH2AX. (G)
PercentagesofgH2AXfocus–positivecellsat the indicatedtimes. (H)CellproliferationofED-40515(−)andJurkatcellsevaluatedby anMTSassay. Data shownare as in (E).
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DNA damage checkpoint to induce transient S/G2-phase arrest and
apoptosis.
ABC induces DSBs due to impaired DNA repair in ATL cells
To characterize DNA damage, we measured chromosome breaks in
mitotic ATL cells after exposure to ABC. The exposure significantly
increased the number of chromosome breaks in ED-40515(−) cells
(Fig. 3A, arrow) but not in Jurkat cells (Fig. 3B). The number of chro-
mosome breaks induced by AZT in ED-40515(−) cells was several times
smaller than that induced by ABC (Fig. 3B, left panel), which cor-
responds with the data in Fig. 1A. We therefore conclude that the ther-
apeutic concentration of ABC as well as that of AZT efficiently induces
DSBs in the chromosomal DNA of ATL cells, as does ionizing radiation.
To monitor the kinetics of DSB repair, we transiently exposed cells
to a high dose of ABC for 12 hours and then monitored the number
of unrepaired DSBs over time by counting the number of subnuclear
foci containing the phosphorylated H2A histone variant (gH2AX).
ED-40515(−) and Jurkat cells displayed comparable numbers of gH2AX
foci after 4 hours, whereas resolution of gH2AX focus formation was
indeed delayed in ED-40515(−) cells, but not in Jurkat cells, even after
48 hours (Fig. 3, C and D). Cellular proliferation was also reduced in
ED-40515(−) cells (Fig. 3E). Thus, ATL cells are severely deficient in
repairing ABC-induced DSBs. We next assessed the performance of
the two major DSB repair pathways, homologous recombination (HR)
and nonhomologous end-joining, in ATL cells. To this end, we monitored
the kinetics of DSB repair after
ionizing radiation. ED-40515(−)
and Jurkat cells displayed very
similar kinetics for DSB repair,
indicating the competence of
the canonical DSB repair path-
ways in these cells (Fig. 3, F to
H). Because HR is responsible for
repairing DSBs generated during
DNA replication (21), we exam-
ined ongoing HR by measuring
the polymerization of RAD51 re-
combinase, the essential HR fac-
tor, at DSB sites in ABC-treated
cells. Treatment with ABC in-
duced RAD51 focus formation co-
localizing with gH2AX foci in
ED-40515(−) cells (Fig. 4, A and
B). This finding suggests that fre-
quent premature termination of
DNA replication resulted in both
the formation of DSBs and the
activation of HR-dependent DSB
repair to a significantly higher
extent in ATL cells than in non-
ATL cells.
A defect in TDP1 is
responsible for the
cytotoxic effect of
ABC on ATL cells
To identify the factors required for
efficient repair of ABC-induced
DNA DSBs, we screened a panel of 48 isogenic mutant chicken
DT40 cell lines deficient in DNA repair factors (22) for sensitivity
to ABC (table S2). The result (fig. S4) was a telling sensitivity profile;
the sensitivity of the five mutant cell lines (Tdp1, Poll, Usp1, Gen1, and
Rad18) to ABC was more than twofold greater than that of the wild-
type DT40 cell line (Fig. 5, A and B, and fig. S5A). Furthermore, the
relative sensitivity of Tdp1-deficient DT40 cells to the six individual
NRTIs correlated with their cytotoxic effect on ATL cells (Figs. 1A
and 5B). These results suggest that a defect in TDP1 might account
for the cytotoxic effect of ABC on ATL cells.
We next investigated TDP1 expression in ATL cells [Gene Expres-
sion Omnibus (GEO) database] according to the Joint Study on Prog-
nostic Factors of ATL Development (23), and found that the level of
TDP1 expression is indeed down-regulated in ATL cells relative to pri-
mary CD4+ T cells (Fig. 5, A and C, and fig. S5B). Likewise, the TDP1
protein and mRNA levels in ATL cell lines (Fig. 5D) and in primary
ATL cells (Fig. 5, E and F, and table S3) were significantly lower than
those in the noninfected T cells and primary CD4+ T cells, respective-
ly. These observations suggest that a defect in TDP1 causes the sensi-
tivity to ABC in ATL cells.
TDP1 removes ABC from DNA ends in vitro
To confirm that TDP1 plays a crucial role in ABC-induced DNA
damage repair, we first examined whether human TDP1 (hTDP1) re-
moved CBV that was covalently associated with the 3′ end of a DNA
Fig. 4. ABC-induced prolonged activation of homologous recombination–
dependent repair in ATL cells. (A) Immunocytochemical staining with DAPI, anti-
gH2AX, and anti-RAD51 recombinase. ED-40515(−) and Jurkat cells were treated with
or without 100 mM ABC for 2 days. The percentages of gH2AX and RAD51 focus–positive cells, defined as cells
containing more than five foci per cell, are shown. (B) Immunocytochemical staining with DAPI, anti-gH2AX, and
anti-RAD51. ED-40515(−) and Jurkat cells were treated with or without 100 mM ABC for 2 days. The merged images
display frequent colocalization of gH2AX and RAD51.
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oligonucleotide (Fig. 6A). We incubated total cell lysates from DT40
Tdp1−/− cells or Tdp1−/− cells complemented with hTDP1, with two
substrate oligonucleotides containing either 3′-CBV or 3′-Tyr. The latter
cellular lysate, but not the former one, efficiently generated the product
that migrated one nucleotide shorter than the substrate (Fig. 6B). The
processing efficacy of TDP1 for 3′-CBV increased in a dose-dependent
manner (Fig. 6C). These biochemical results demonstrate that TDP1
removes 3′-blocking CBV efficiently in vitro.
TDP1 catalytic activity is required for cellular tolerance to ABC
To verify the importance of TDP1 in cellular tolerance to ABC, we
depleted TDP1 and reconstituted TDP1-deficient cells with a TDP1
transgene. TDP1 small interfering RNA (siRNA)–treated Jurkat cells
were more sensitive to ABC than the control siRNA–treated Jurkat
cells (Fig. 7A, lanes 4 and 2, respectively). Conversely, reconstitution
of MT-2 cells with human wild-type TDP1markedly increased cellular
tolerance to ABC (Fig. 7B and fig. S6, A to C). These data indicate that
TDP1 plays an important role in cellular tolerance to ABC. The ec-
topic expression of TDP1WT did not reverse the sensitivity of MT-2
cells to AZT (fig. S7), suggesting that hTDP1 eliminates AZT less ef-
ficiently than ABC. We conclude that the attenuated functionality of
TDP1 is responsible for a high sensitivity to ABC in ATL cells.
To confirm that TDP1 catalytic activity is required for cellular tol-
erance to ABC, we prepared two mutant TDP1 transgenes [H263A and
H493R (13, 24)] and a wild-type TDP1 transgene (25) and ectopically
expressed them in MT-2 cells to generate MT-2/TDP1H263A, MT-2/
TDP1H493R, and MT-2/TDP1WT cells, respectively (fig. S6, A to C).
Ectopic expression of TDP1WT greatly increased MT-2 cell tolerance
to ABC, but not that of the two mutant transgenes (Fig. 7B). Likewise,
the phenotypes of the MT-2/TDP1H263A and MT-2/TDP1H493R cells
were very similar to that of the parent MT-2 cells in terms of cellular
response to ABC, including cell cycle arrest at the S phase (Fig. 7C),
apoptosis (Fig. 7D), prolonged gH2AX focus accumulation (Fig. 7, E
and F), and inhibition of cellular proliferation (Fig. 7G). We therefore
conclude that TDP1 catalytic activity is required for cellular tolerance
to ABC. This conclusion is supported by our data shown above and
the previous reports showing that TDP1 can remove NRTIs localized
at the 3′ ends of single-stranded oligonucleotides in vitro, because
TDP1 eliminates trapped TopI from the 3′ ends of DNA strands in vivo
(13, 26, 27).
CPT11 and veliparib enhance the lethality of ABC on ATL cells
CPT11 sensitivity is the classical hallmark of TDP1 loss. We verified a
strong cytotoxic effect of CPT11 on ED-40515(−) cells (fig. S8A). We
then tested whether a minimal dose of CPT11 synergistically increased
the lethality of ABC on ATL cells. CPT11 significantly enhanced the
lethality of ABC against ATL cells, with a low combination index
(CI < 0.7; fig. S8B).
Furthermore, TDP1 removes trapped TopI from DNA by collabor-
ating with poly(adenosine diphosphate–ribose) polymerase (PARP)
(28). We thus theorized that combining ABC with PARP inhibitors
might have a synergic cytotoxic effect on ATL cells by completely wip-
ing out the residual activity of TDP1 in ATL cells. We then tested min-
imum doses of veliparib, which inhibits the catalytic activity of PARP
without trapping PARP at DNA damage sites (29). Although veliparib
alone had no obvious toxic effect on ATL cells, it significantly en-
hanced the lethality of ABC on ATL cells, with a low CI (<0.7; fig.
S8C). These results suggest that a combination of ABC with CPT11
and/or PARP inhibitors could be a potent new therapeutic strategy
against ATL.
ABC inhibits the growth of ATL cell xenografts inNOD/SCIDmice
Finally, we tested the in vivo effect of ABC on ATL cell growth
using an ATL xenograft model. Nonobese diabetic/severe combined
Fig. 5. Impaired TDP1
responsible for ATL
cell sensitivity to ABC.
(A) Venn diagram of
DNA repair genes defec-
tive in mutant chicken
DT40 cell lines sensi-
tive to ABC and down-
regulated DNA repair
genes in ATL cells. (B)
Relative sensitivities of
Tdp1-deficient DT40
cells treated with six
NRTIs. Results are ex-




levels based on microarray data from the GEO database (available
at www.ncbi.nlm.nih.gov/geo/; accession number GSE33615). The
relative expression levels of TDP1 in peripheral blood cells ob-
tained from ATL patients and normal healthy donor controls are shown.
The box plot uses the median, the approximate quartiles, and the lowest
and highest data points to convey the level, spread, and symmetry of the
distribution of data values. Statistical analysis was performed using Student’s
t test to compare the mRNA expression levels between the ATL cases (n = 52)
and the normal controls (n = 21). (D) Western blot analysis of TDP1 ex-
pression in HTLV-1–infected cell lines and in Jurkat cells. (E) Quantitative
reverse transcription–polymerase chain reaction (RT-PCR) for TDP1 in pri-
mary ATL cells from 10 patients and in primary CD4+ T cells from 5 healthy
donors. Data shown as in (C). (F) Western blot analysis of TDP1 in primary
ATL cells from two patients and primary CD4+ T cells from two healthy
donors.
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immunodeficient (NOD/SCID) mice were inoculated with ED-40515(−)
cells and treated daily with ABC via oral gavage at a dose of 75 mg/kg
per day, which is comparable to 410 mg once daily of orally administered
ABC in humans. Orally administered ABC significantly inhibited the
growth of ATL tumor grafts (Fig. 8A) and improved survival (Fig. 8B).
DISCUSSION
In this report, we demonstrate that ABC specifically and potently kills
ATL cells. ABC triggers apoptosis by inducing DSBs in host chromo-
somal DNA. The most likely mechanism for DSB induction is that
ABC is converted to the triphosphated CBV in cells and then
incorporated into host chromosomal DNA by replicative DNA poly-
merases, leading to premature termination of DNA replication, col-
lapse of the replication fork, and DSB formation (Fig. 9). Thus, ABC
is an effective chain terminator not only in the reverse transcription
of retroviral DNA but also in the replication of host chromosomal
DNA in ATL cells. This is totally unexpected because long-term treat-
ment with ABC is well tolerated, causing only few side effects in HIV-
1 patients. ABC has also been shown to be virtually nontoxic to bone
marrow progenitor cells and leukemic cell lines (17). Our study iden-
tifies efficient DSB formation as the unique mechanism underlying the
specific killing of ATL cells by the antiretroviral agent ABC.
Three mechanisms can inhibit NRTI genotoxicity. First, NRTIs are
not potent inhibitors of replicative DNA polymerases (30, 31). Second,
the catalytic pocket of replicative DNA polymerases is able to strin-
gently discriminate between triphosphated NRTIs and normal nucleo-
tides, with proofreading activities considered also as a contributing
factor. Third, host DNA repair factors may be able to remove NRTIs
when they are misincorporated into the 3′ end of primers by replica-
tive DNA polymerases. The third mechanism accounts for the high
toxicity of ABC to ATL cells, which, unlike non–HTLV-1–infected cells,
are almost entirely unable to repair ABC-induced DSBs (Fig. 3, C and
D). Moreover, our study demonstrates that a TDP1 defect is primarily
responsible for the potent and selective cytotoxic effect of ABC on
ATL cells. TDP1 can eliminate CBV misincorporated by replicative DNA
polymerases into the 3′ ends (Fig. 6) because TDP1 eliminates TopI
trapped at the 3′ ends of DNA cleavage (13) and oxidative 3′-blocking
lesions (32). It is surprising that TDP1 could remove the 3′-blocking
nucleotide analog that was not eliminated by the proofreading nuclease
of replicative DNA polymerases. TDP1 seems to remove AZT from
3′ ends with considerably less efficiency than ABC because ectopic ex-
pression of a TDP1 transgene in MT-2 cells greatly increased cellular
tolerance to ABC but not to AZT (Fig. 7B and fig. S7). We thus pro-
pose that ABC is a more potent chemotherapeutic agent against ATL
than AZT. The current study also suggests that a therapy that combines
ABC and CPT11 or a PARP inhibitor such as veliparib would provide
a novel therapeutic strategy against ATL by enhancing the cytotoxic
effect of ABC with minimum side effects on normal cells (fig. S8).
The molecular mechanism underlying reduced TDP1 gene expres-
sion is unclear. However, the current study reveals that the transcription-
al status of the TDP1 gene may be a reliable biomarker for predicting the
efficacy of ABC in anti-malignancy therapy. In addition, a recent report
showing the defect of TDP1 in several lung cancer cell lines suggests
the much broader indication of ABC to other cancers (33).
Finally, we demonstrate that ABC efficiently inhibits the growth
of ATL cell xenografts in NOD/SCID mice. We administered ABC at
75 mg/kg per day orally. The plasma concentration of ABC in the
mice was comparable to that in HIV-1 patients taking orally 410 mg
of ABC once daily (34). Thus, the daily ABC dose given toHIV-1 patients
might be sufficient for treating ATL, and our findings establish a ratio-
nale to expand its use for ATL patients. Moreover, ABC might
prove useful for treating HTLV-1 asymptomatic carriers. A high
HTLV-1 proviral load in the asymptomatic carrier promotes the pro-
gression to ATL and other HTLV-1–associated diseases (35). We here
show that ABC is useful for suppressing HTLV-1–infected cells other
than ATL cells (Fig. 1). In addition, ABC has very few side effects,
even during long-term treatment. Thus, ABC would be an effective
prophylactic agent in both HTLV-1 carriers with a high proviral
Fig. 6. TDP1 removes ABC from DNA ends in vitro. (A) Schematic dia-
gram of in vitro biochemical assays for TDP1 activity. Both substrates con-
tained the same sequence and conjugated CBV or tyrosine as a 3′-blocking
lesion via a phosphodiester linkage. The substrates (S) were radiolabeled at
the 5′ end with 32P. The products that are removed from the 3′-blocking
lesion from the substrates by TDP1 are labeled “P.” Y: Tyr. (B) A representative
gel demonstrating the processing of the indicated substrates by increasing
amount of total cell lysates from Tdp1−/− DT40 cells or Tdp1−/− DT40 cells
stably transfected with hTDP1 transgene. The substrates were incubated
with serially diluted total cell lysates ranging from 0.03 to 7.5 mg. Reaction
proceeded for 15 min at 25°C before being quenched and analyzed on 16%
denaturing gels. (C) The percentage of product yield is plotted against
increasing lysate concentration. Results are expressed as means ± SD of
three independent experiments.
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Fig. 7. TDP1 catalytic activity re-
quirement for cellular tolerance
to ABC. (A) Control siRNA or siTDP1
mixture was transfected into Jurkat
cells. Depletion of TDP1 expression was confirmed by Western blot analysis 48 hours after transfection (right panel). Jurkat cells transfected with control
siRNA or siTDP1 were treated with or without 300 mM ABC for 48 hours. MTS values of treated relative to untreated cells are shown (left panel). Results are
expressed as means ± SD of three independent experiments. (B) MT-2 cells stably transfected with either wild-type (WT) TDP1, H263A TDP1, or H493R
TDP1 transgenes. Stably transfected clones and control cells (mock) were treated with the indicated dose of ABC for 48 hours. Western blot analysis was
conducted for expression of transgenes (right panel). Data shown as in (A, left panel). (C) Cell cycle analysis is shown as in Fig. 2A. MT-2/TDP1WT, MT-2/
TDP1H263A, and MT-2/TDP1H493R cells were treated with or without 100 mM ABC for 24 hours and subjected to flow cytometry. (D) The extent of apoptosis is
shown as the percentage of annexin V–positive cells (y axis). Cells were treated as in (C). (E) The indicated cells were treated as in Fig. 3C. Data shown as in
Fig. 3C. (F) Statistical analysis of data in (E). MT-2/TDP1WT cells, but not MT-2/TDP1H263A or MT-2/TDP1H493R cells, are resistant to ABC. (G) Proliferation of the
indicated cells is shown as in Fig. 3E.
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Fig. 8. ABC inhibits the growth of ATL
cell xenografts in NOD/SCID mice. (A) Tu-
mor sizes of xenografted NOD/SCID mice
treated with or without ABC. The mean sizes
of individual tumors were plotted (control
group, n = 7; ABC group, n = 6). P values
were determined using Student’s t test
(*P < 0.05). Error bars represent the SEM.
(B) Kaplan-Meier survival curves for the
ABC-treated and control mice. P values were
determined using the Wilcoxon test.
Fig. 9. Specific lethality of ABC on ATL cells due to a defect in TDP1.
ABC is phosphorylated in a unique stepwise anabolism and is converted to
the triphosphate of CBV. During DNA synthesis, triphosphorylated ABC was
incorporated into host chromosomal DNA by replicative DNA polymerases,
leading to premature termination of DNA replication. In normal cells, TDP1
removes ABC quickly and DNA synthesis continues. However, in HTLV-1(+)
cells, the collapse of the replication fork is induced because of the deficien-
cy of TDP1, leading to DSB formation and apoptosis.
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load and patients with HTLV-1–associated myelopathy/tropical




ED-40515(+) is an interleukin-2 (IL-2)–dependent T cell line of leu-
kemic cell origin established from an ATL patient (36). ED-40515(−)
is an IL-2–independent subclone of ED-40515(+) (37). SY is an IL-2–
dependent HTLV-1–infected T cell line derived from a nonleukemic
cell clone of ED-40515(+) from an ATL patient. ATL-43T is an IL-2–
dependent T cell line established from double-negative (CD4−, CD8−)
leukemic cells from a patient with ATL (38). SYK-11L(+) is a leukemic
cell line from ATL tumor cells in an in vivo cell proliferation model
using SCID mice (39). Hut-102 is an IL-2–independent T cell line from
a patient with mycosis fungoides (40). MT-2 is a stably transformed
HTLV-1–infected cell line, as previously reported (36). A summary of
HTLV-1–infected and ATL cell lines is presented in table S4. Jurkat
and H9 are IL-2–independent non–HTLV-1–infected human T cell
lines. SU-DHL-6 is a non–HTLV-1–infected human B cell line. These
cells were maintained in RPMI 1640 medium (Nacalai Tesque) con-
taining 10% fetal bovine serum (FBS) and penicillin (100 U/ml), strep-
tomycin (100 mg/ml), and L-glutamine (0.292 mg/ml) (PSG) (Invitrogen).
The IL-2–dependent cell lines were maintained in the same medium
with 0.5 nM recombinant human IL-2 (a gift from Shionogi Pharma).
Human embryonic kidney (HEK) 293T cells were maintained in
Dulbecco’s modified Eagle’s medium (Nacalai Tesque) containing
10% FBS and 1% PSG. The chicken DT40 cell lines used in this study
were obtained from the Laboratory of Radiation Genetics, Graduate
School of Medicine, Kyoto University (Kyoto, Japan). All mutant cell
lines were previously authenticated (references provided in table S2).
DT40 Tdp1−/− and Tdp1−/− hTDP1 cells (32) were gifts from Y. Pommier
[Laboratory of Molecular Pharmacology, Center for Cancer Research,
National Institutes of Health (NIH), Bethesda, MD]. The DT40 cells
were cultured at 39.5°C with 5% CO2 in RPMI 1640 medium supple-
mented with 1% chicken serum (Gibco BRL), 10% FBS (Sigma-Aldrich),
10−5 M b-mercaptoethanol (Nacalai Tesque), penicillin (100 U/ml),
streptomycin (100 mg/ml; Nacalai Tesque), and L-glutamine (0.292 mg/ml;
Nacalai Tesque).
Reagents and antibodies
ABC, AZT, ddI, d4T, 3TC, and TDF were donated by the NIH through
the AIDS reagent program. ABC was purchased from Sigma-Aldrich
(SML0089) and Carbosynth (NA10019). Camptothecin (TG4110) and
veliparib (ABT-888) were purchased from TopoGEN and Selleck
Chemicals, respectively. These chemicals were dissolved in 100% di-
methyl sulfoxide (DMSO, Nacalai Tesque) to a stock concentration of
10 to 500 mM and were stored at −20°C. Natural-type human IFN-a
(Sumiferon) was purchased from Dainippon Sumitomo Pharma. Mouse
anti-gH2AX (JBW301) was purchased from Merck Millipore, rabbit
anti-RAD51 (H-92) was purchased from Santa Cruz Biotechnology,
and rabbit anti-RAD51 (70–001) and mouse anti-RAD51 (B01P) were
purchased from BioAcademia and Abnoba, respectively. Phycoerythrin–
annexin V was purchased from BD Biosciences, and fluorescein iso-
thiocyanate (FITC)–annexin V from BioLegend. PI (Nacalai Tesque)
was dissolved in phosphate-buffered saline (PBS) to a stock concen-
tration of 2 mg/ml. Rabbit anti-TDP1 (ab4166) was purchased from
Abcam. Anti–b-actin (AC-15, A5441) was purchased from Sigma-Aldrich.
Human cell killing assay
To assess the sensitivity of human cell lines to the NRTIs with or with-
out IFN-a or veliparib, 1 × 104 to 2 × 104 cells were seeded in 96-well
flat-bottomed culture plates (final volume of 100 ml per well) and cul-
tured for 0 to 96 hours at 37°C. Twentymicroliters of CellTiter 96 AQueous
One solution from a cell proliferation assay kit (Promega) was added
to each well, after which cell survival was determined by measuring the
absorbance intensity at 490 nm using an ALVO X-3 (PerkinElmer). The
absorbance values were normalized to those of controls.
Cell cycle analysis
The pretreated cells were fixed with chilled 70% ethanol for 30 min at
4°C and then stained with PI (5 mg/ml; Nacalai Tesque) in the pres-
ence of 1% bovine serum albumin (BSA; Nacalai Tesque) and ribonu-
clease (100 mg/ml; Sigma-Aldrich) for 30 min at room temperature.
Immediately after staining, evaluation was performed using a FACS-
Calibur analyzer, and the data were analyzed using ModFit software.
DMSO treatment was used as a negative control, and Adriamycin
(1 mg/ml) treatment was used as a positive control.
Apoptosis assay
The pretreated cells were stained with FITC–annexin V (BioLegend)
and PI for 10 min at 4°C. After staining, analysis was performed im-
mediately using a FACSCalibur analyzer. DMSO treatment was used
as a negative control, and Adriamycin (1 mg/ml) treatment was used as
a positive control.
Chromosomal analysis
The cells were cultured with colcemid (50 ng/ml) for 2 hours at 37°C,
fixed with Carnoy’s solution, and placed on a glass slide. The slide was
stained with 3.5% Giemsa (Nacalai Tesque) for 10 min, and the cells
were examined by microscopy. Cells containing one chromosome break
were defined as chromosome break–positive.
Cell irradiation
Cells were irradiated with 2 Gy of 135Cs g-radiation using a Gamma-
cell 40 Exactor (Best Theratronics).
Immunofluorescence staining
Prepared cells were placed on a glass slide via Cytospin. The cells were
fixed with 4% formaldehyde (Nacalai Tesque) and washed with PBS.
Next, the fixed cells were permeabilized using 0.1% NP-40/PBS for 10 min.
After blocking with 3% BSA/PBS–Tween 20 for 15 min, the cells were
incubated with the primary antibody at 37°C. Cells were then stained
with Alexa Fluor 594 goat anti-mouse immunoglobulin G (IgG) (H+L)
antibody, Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody, or Alexa
Fluor 488 goat anti-mouse IgG (H+L) antibody (Molecular Probes) and
DAPI (H-1200, Vector Laboratories) and observed using a fluores-
cence microscope (BZ-8100, Keyence).
Evaluation of relative cellular sensitivity to NRTIs
To assess the sensitivity of DT40 cells to various NRTIs, 1 × 103 DT40
cells were seeded in 96-well black dishes (final volume of 100 ml per
well) and continuously exposed to 25 mM of the indicated drug for
48 hours. CellTiter-Glo Luminescent Cell Viability Assay solution
R E S EARCH ART I C L E
Tada et al. Sci. Adv. 2015;1:e1400203 24 April 2015 9 of 13
(100 ml; Promega) was directly added to each well, and cell survival was
determined by measuring the luminescence intensity using ALVO X-3
(PerkinElmer). Wild-type cells were examined in each assay. To evalu-
ate the cellular sensitivity of each mutant relative to wild-type cells, the
sensitivity of each mutant was normalized to that of the untreated cells.
The values of the mutant and wild-type cell lines were converted to a
logarithmic scale (base 2). Each value was plotted on a bar graph.
Real-time PCR
Total RNA was isolated from human samples using a High Pure RNA
Isolation Kit (Roche). First-strand complementary DNA (cDNA) was
generated using the PrimeScript II 1st strand cDNA Synthesis Kit
(Takara). cDNA was amplified in a Thermal Cycler Dice Real Time
System II (Takara) using SYBR Premix Ex Taq II (Takara). The data
were normalized to the corresponding values for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The expression levels of the
cells relative to normal cells (=1) are shown in Fig. 5 and fig. S5. Error
bars represent SDs. The primers used were TDP1 forward, 5′-AGG-
CAGCCTTGGACAGATT-3′; TDP1 reverse, 5′-GGTCAGCTGAGAC-
TTCTGGC-3′; GAPDH forward, 5′-GAAGGTGAAGGTCGGAGTC-3′;
and GAPDH reverse, 5′-GAAGATGGTGATGGGATTTC-3′.
Western blot
A total of 5 × 106 cells were lysed using ice-cold lysis buffer (MPER,
Thermo Scientific) containing 1 mM phenylmethylsulfonyl fluoride,
phosphatase inhibitor cocktail (Roche), and protease inhibitor cocktail
(Nacalai Tesque), followed by centrifugation at 13,000 rpm for 15 min
at 4°C. The cell lysates were mixed with an equal volume of twofold
concentrated sample buffer (Bio-Rad Laboratories) containing b-
mercaptoethanol (Nacalai Tesque) and were treated for 5 min at
100°C. Western blot was performed as described previously (41).
Isolation of primary CD4 T cell and ATL cell samples
This project was approved by the Institutional Review Board of Kyoto
University Hospital, and all participants provided written informed
consent in accordance with the Declaration of Helsinki. Peripheral
blood mononuclear cells were isolated from healthy donors and 10
ATL patients through Ficoll gradient centrifugation. Peripheral blood
mononuclear cells isolated from two acute-type ATL patients through
Ficoll gradient centrifugation were used for Western blot (Fig. 5F).
These two patients’ characteristics are provided in table S3. The CD4+
T cell population was isolated using an EasySep Human CD4+ T Cell
Enrichment Kit (STEMCELL Technologies).
In vitro biochemical assays for TDP1 activity
All single-standard DNA substrates share the commons sequence of
5′-TCCGTTGAAGCCTGCTTT-3′. Oligonucleotides were synthesized
in the reversed direction, as described previously (42). CBV was pre-
pared according to the literature (43). Total cell lysates fromDT40 Tdp1−/−
and Tdp1−/− hTDP1 cells were prepared in the same manner as previously
described (44). The protein concentration of lysates was determined by
Bradford protein assay (Quick Start protein assay, Bio-Rad Laboratories).
To prepare DNA substrate, oligonucleotides with 3-phosphotyrosine and
CBV linkages synthesized were incubated with [g-32P]adenosine tri-
phosphate (NEG502A, PerkinElmer Life Sciences) and T4 polynucleotide
kinase (Takara) for 5′-end labeling. After being purified using a nucleotide
removal kit (Qiagen), 1 nM labeled oligonucleotide was incubated with cell
lysates at 25°C for 15 min. Samples were separated by 16% denaturing
polyacrylamide gel electrophoresis (7 M, urea). Dried gel was exposed
on the imaging plate (Fujifilm) and then scanned in Fuji Bas 2500 system.
Quantification was performed by Image Gauge software (Fujifilm).
RNA interference
To evaluate the role of TDP1 in the cell sensitivity to ABC, we knocked
down TDP1 in Jurkat cells using specific siRNA. Transient TDP1
knockdown was achieved using the siGENOME SMARTpool (Ther-
mo Scientific). A total of 5 × 106 Jurkat cells were electroporated with
either nontargeted siRNA (Stealth RNAi NEGATIVE CONTROL,
Invitrogen) or hTDP1-specific siRNA (20 pmol/ml) using the Amaxa
Cell Nucleofector System (Lonza). Knockdown efficiency was deter-
mined by quantitative PCR 24 hours after transfection and Western
blot 48 hours after transfection.
Plasmid constructs
Plasmids encoding FLAG-TDP1 wild type, FLAG-TDP1 H263A, and
FLAG-TDP1 H493R were a gift from Y. Pommier (NIH). H263A and H493R
are inactive TDP1 mutants; the latter causes spinocerebellar ataxia with
axonal neuropathy (SCAN1).Wild-type, H263A, and H493R FLAG-TDP1
were cloned into the lentiviral vector CSII-CMV-MCS-IRES-hrGFP.
Generation of MT-2 cells reconstituted with hTDP1
Wild-type, H263A, and H493R FLAG-TDP1–expressing lentiviral
vectors were prepared as described previously (41). MT-2 cells were
infected with each viral vector. Confirmation of infectivity was based
on human recombinant green fluorescent protein (hrGFP) expression,
and the expression level of TDP1 in each group of infected MT-2 cells
was verified by Western blot with rabbit anti-TDP1.
Preparation of ATL model mice
The rapid tumor formation by the ATL cell line in NOD/SCID mice
has been previously established (38, 45). Four-week-old NOD/SCID
mice were purchased from CLEA Japan. Fourteen mice were anesthe-
tized with ether, and 4 × 107 ED-40515(−) cells were subcutaneously
inoculated into the posterior cervical lesion. Beginning 2 weeks after
inoculation, the long and short axes were measured weekly. The tumor
volume was approximated as (long axis) × (short axis)2. All experiments
were performed under the approved protocols of the Institute of Lab-
oratory Animals, Graduate School of Medicine, Kyoto University.
Administration of ABC
ABC dissolved in water was administered orally to mice at a dose of
75 mg/kg per day on weekdays from day 0 to day 20. The control mice
received an equivalent amount of water.
Analysis of combined treatment effects
The synergistic effects of the combined treatments were analyzed
using the Chou-Talalay method (46). The CI of each combined treat-
ment was calculated using CompuSyn software, and CIs of 0.3 to 0.7,
0.1 to 0.3, and <0.1 were defined as synergism, strong synergism, and
very strong synergism, respectively (47).
Statistical analysis
The statistical significance of the differences between the drug-treated
and control cultures was determined using Student’s t test or the c2
test. The statistical significance of the survival rates was determined
using the Wilcoxon test.
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